Abstract
Cariprazine is a dopamine D3/D2 and serotonin 5-HT1A receptor partial agonist. This study evaluated the safety, tolerability, pharmacokinetics (PK), and exploratory efficacy of cariprazine and its 2 major active metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR) in pediatric patients with ASD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Paper Title
Journal
Date
